Trials / Completed
CompletedNCT01209793
Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety and Tolerability of Intravenously Administered REGN846 (SAR302352) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is being conducted to assess the safety and tolerability of a single ascending intravenous (IV) dose of REGN846 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGN846 | 5 IV cohorts (Dose 1, 2, 3, 4, 5) |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-09-27
- Last updated
- 2012-06-01
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01209793. Inclusion in this directory is not an endorsement.